Major Events - Enjie Co., Ltd. is planning to acquire 100% equity of Zhongke Hualian and will suspend trading starting December 1, 2025 due to uncertainties surrounding the transaction [4] - ST Tianrui's controlling shareholder is planning a change in company control, leading to a trading suspension starting December 1, 2025, expected to last no more than two trading days [5] - Jiarong Technology intends to raise no more than 1 billion yuan through a private placement and acquire 100% of Hangzhou Lanran [6][7] - Baili Tianheng's wholly-owned subsidiary received a milestone payment of 250 million USD from BMS related to a collaboration agreement [8] - Jiangxi Copper is planning to acquire shares of the overseas listed company SolGold Plc, with a non-binding cash offer of 26 pence per share, currently in the informal offer stage [9] - China Shenhua's subsidiary successfully completed a 168-hour trial run of its power generation unit, marking a significant milestone in its expansion project [10] - ST Dongyi faces the risk of bankruptcy due to unsuccessful restructuring efforts, which could lead to stock delisting [11] - Huayang Co., Ltd. has launched a high-performance carbon fiber project with an annual production capacity of 200 tons, applicable in various high-tech fields [12] - Dameng Data's general manager has had his detention lifted by the local authorities [13] Shareholding Changes - Zhongwei Company plans to reduce its stake by no more than 1% through block trading, equating to approximately 6.26 million shares [14] - Yulide's directors plan to collectively reduce their holdings by no more than 0.0313%, totaling up to 35,000 shares [15] - Shengnuo Bio's vice president and a board member plan to reduce their holdings by no more than 0.024%, totaling up to 37,600 shares [16] Major Contracts - Aoride plans to sign a comprehensive technical service agreement with Company X, with a total contract value of approximately 635 million yuan [17]

Company Focus - Enjie Co., Ltd. plans to acquire 100% equity of Zhongke Hualian, leading to a stock suspension [2] - Canadian Solar Inc. and its controlling shareholder plan to establish a joint venture to adjust their U.S. market operations [3] - Jiarong Technology intends to acquire 100% of Hangzhou Lanan, with stock resuming trading [3] Equity Changes - ST Tianrui's controlling shareholder is planning a change in control, resulting in stock suspension [4] Shareholding Changes & Buybacks - Shanghai Chuangtou intends to reduce its stake in Zhongwei Company by no more than 1% [5] Operations & Performance - China Shenhua's subsidiary successfully completed a 168-hour trial run of its power generation unit, transitioning to commercial operation [6] - Baillie Tianheng received a milestone payment of $250 million from Bristol-Myers Squibb for the iza-bren project [7] - Jiangxi Copper is in the informal offer stage to acquire shares of SolGold Plc [8] - Aorede plans to sign a 635 million yuan computing power procurement agreement [9] - Maiwei Bio's clinical research for 9MW1911 shows significant reductions in acute exacerbation rates for COPD patients [10] - Huayang Co. has launched a high-performance carbon fiber project with an annual production capacity of 200 tons [10] Financing & Capital Increase - Ganfeng Lithium plans to issue $100 million in exchangeable notes to the China-Africa Development Fund [11] Stock Price Fluctuations - Tongyu Communications confirmed normal operations amid stock price fluctuations [12] - Rongji Software reported normal operations despite stock price declines [13] Other - Xianglou New Materials' application for a specific stock issuance has been accepted by the Shenzhen Stock Exchange [15] - JinkoSolar received a prepayment of 220 million yuan for a fire incident at its battery workshop [15] - Dameng Data's general manager has had his detention lifted [15] - Dongpeng Beverage has received approval from the CSRC for its overseas listing [16]

Core Viewpoint - SystImmune has received a milestone payment of $250 million from BMS as part of a collaboration agreement for the development and commercialization of the BL-B01D1 project, a dual-target ADC with significant clinical value and market potential [1][3]. Group 1 - SystImmune is focused on addressing unmet clinical needs in the field of biomedicine, particularly in tumor macromolecule therapies, and aims to establish global commercialization capabilities by 2029 [1]. - The collaboration agreement includes an upfront payment of $800 million from BMS, with potential additional payments reaching up to $5 billion based on specific milestones, and a total potential deal value of up to $8.4 billion [2]. - As of March 7, 2024, SystImmune has received an irrevocable and non-deductible upfront payment of $800 million from BMS [2]. Group 2 - SystImmune will be exclusively responsible for the development and commercialization of BL-B01D1 in mainland China, while BMS will handle the development and commercialization in other global regions [2]. - The agreement stipulates that SystImmune is eligible for additional payments of up to $250 million based on recent or contingent milestones, and up to $7.1 billion upon achieving specific development, registration, and sales milestones [3].

Core Viewpoint - Several companies are undergoing significant corporate actions, including acquisitions, capital raising, and operational milestones, which may present investment opportunities and market implications. Group 1: Corporate Actions - Enjie Co., Ltd. is planning to acquire 100% equity of Zhongke Hualian and will suspend trading starting December 1, 2025 due to uncertainties surrounding the transaction [3] - ST Tianrui's controlling shareholder is planning a change in company control, leading to a trading suspension from December 1, 2025, expected to last no more than two trading days [4] - Jiarong Technology intends to raise up to 1 billion yuan through a private placement and acquire 100% of Hangzhou Lanran, with the transaction making the latter a wholly-owned subsidiary [5] - Jiangxi Copper is in the process of making non-binding cash offers to acquire shares of SolGold Plc at 26 pence per share, currently holding 12.19% of the company [7] Group 2: Financial Milestones - Baillie Gifford's subsidiary SystImmune received a milestone payment of $250 million from Bristol-Myers Squibb related to a collaboration agreement, with potential future payments totaling up to $7.1 billion [6] Group 3: Operational Developments - China Shenhua's subsidiary successfully completed a 168-hour trial run of its 3rd unit at the Beihai Phase II project, which is a key energy development project in Guangxi [8] - Huayang Co., Ltd. has launched a 200-ton annual production project for high-performance carbon fiber, which is expected to serve various high-tech industries [11] Group 4: Shareholder Actions - Zhongwei Company’s major shareholder plans to reduce its stake by up to 1% through block trading [14] - Yulide's directors plan to collectively reduce their holdings by no more than 0.0313% of the company's total shares [15] - Saint Noble Bio's executives plan to reduce their holdings by no more than 0.024% of the company's total shares [16] Group 5: Contracts and Agreements - Aoride plans to sign a comprehensive technical service agreement with Company X, with a total contract value of approximately 635 million yuan [18]

Core Insights - SystImmune, a wholly-owned subsidiary of the company, has received a milestone payment of $250 million from Bristol-Myers Squibb (BMS) [1] - The company is eligible for up to an additional $250 million in near-term or contingent payments, as well as up to $7.1 billion in further payments upon achieving specific development, registration, and sales milestones [1] - The milestone payments outlined in the collaboration agreement are subject to certain conditions, and the final milestone payments remain uncertain [1]

Core Insights - SystImmune, a wholly-owned subsidiary of Baillie Gifford, received a milestone payment of $250 million from Bristol-Myers Squibb, with the actual amount subject to bank fees [1] - The company has the potential to receive up to an additional $250 million in near-term or contingent payments, as well as up to $7.1 billion in further payments upon achieving specific development, registration, and sales milestones [1] - The milestone payments outlined in the collaboration agreement are contingent upon certain conditions, indicating uncertainty regarding the final amounts [1]

一、协议前期进展情况 2023 年 12 月 11 日，四川百利天恒药业股份有限公司（以下简称"公司"） 全资子公司 SystImmune,Inc.（以下简称"SystImmune"）与百时美施贵宝（以下 简称"BMS"，纽交所代码：BMY）就 iza-bren（BL-B01D1、EGFR×HER3 双抗 ADC）项目达成独家许可与合作协议（以下简称"合作协议"）。具体内容详见 公司于 2023 年 12 月 12 日披露于上海证券交易所网站（www.sse.com.cn）的《四 川百利天恒药业股份有限公司关于全资子公司 SystImmune 与百时美施贵宝就 BL-B01D1 的开发和商业化权益达成全球战略合作协议的公告》（公告编号： 2023-057）。 截至 2024 年 3 月 7 日，公司已收到由 BMS 支付的 8 亿美元不可退还且不可 抵扣的首付款（实际到账金额须扣除银行手续费）。具体内容详见公司于 2024 年 3 月 11 日披露于上海证券交易所网站（www.sse.com.cn）的《四川百利天恒药业 股份有限公司自愿披露关于收到与百时美施贵宝就 BL-B01D1 开发与商业化许可 协议 8 ...

Core Viewpoint - SystImmune, a wholly-owned subsidiary of Baillie Gifford (688506.SH), has received a milestone payment of $250 million from BMS, with potential for additional payments totaling up to $2.5 billion in the near term and up to $7.1 billion in further payments upon achieving specific development, registration, and sales milestones [1] Group 1 - The company has received a milestone payment of $250 million from BMS [1] - The collaboration agreement allows for additional payments of up to $2.5 billion based on future milestones [1] - There is potential for further payments totaling up to $7.1 billion upon reaching specific development, registration, and sales milestones [1]

Core Viewpoint - SystImmune, a wholly-owned subsidiary of Baillie Gifford (688506.SH), has received a milestone payment of $250 million from BMS, with potential for additional payments totaling up to $71 billion based on future development and sales milestones [1] Group 1 - The company has received a milestone payment of $250 million from BMS [1] - The collaboration agreement allows for additional payments of up to $250 million for near-term or contingent payments [1] - There is potential for further payments of up to $7.1 billion upon achieving specific development, registration, and sales milestones [1] Group 2 - The milestone payments are contingent upon meeting certain conditions, indicating uncertainty regarding the final amounts [1]

Core Viewpoint - The company is set to hold a performance briefing on December 4, 2025, to discuss its Q3 2025 results and address investor inquiries [2][3][4]. Group 1: Meeting Details - The performance briefing will take place on December 4, 2025, from 15:00 to 16:00 [6]. - The meeting will be conducted in an online text interaction format [3][5]. - Investors can participate by logging into the Shanghai Stock Exchange Roadshow Center [5][6]. Group 2: Participation and Inquiry - Investors can submit questions from November 28, 2025, to December 3, 2025, before 16:00 through the Roadshow Center or via the company's email [2][7]. - The company will address commonly asked questions during the briefing [3][7]. Group 3: Attendees - Key attendees include the Chairman, General Manager, Chief Scientific Officer, and independent directors [4].